Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Descrizione completa

Dettagli Bibliografici
Autori principali:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Altri autori:	BSH Committee
Natura:	Journal article
Lingua:	English
Pubblicazione:	Wiley 2023

Documenti analoghi

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
di: McMullin, M, et al.
Pubblicazione: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
di: McMullin, M, et al.
Pubblicazione: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
di: McLornan, D, et al.
Pubblicazione: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
di: Reilly, J, et al.
Pubblicazione: (2014)

Guideline for the diagnosis and management of myelofibrosis.
di: Reilly, J, et al.
Pubblicazione: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
di: Bassiony S, et al.
Pubblicazione: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
di: Verstovsek, S, et al.
Pubblicazione: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
di: P. Harrington, et al.
Pubblicazione: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
di: Mead, AJ, et al.
Pubblicazione: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
di: Salisbury, RA, et al.
Pubblicazione: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
di: Mclornan, D, et al.
Pubblicazione: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
di: Mesa, RA, et al.
Pubblicazione: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
di: Ken I. Mills, et al.
Pubblicazione: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
di: Reilly, J, et al.
Pubblicazione: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
di: Reilly, J, et al.
Pubblicazione: (2014)

Low-dose thalidomide in myelofibrosis
di: Robert Weinkove, et al.
Pubblicazione: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
di: Mead, A, et al.
Pubblicazione: (2019)

Guideline for the investigation and management of eosinophilia
di: Butt, N, et al.
Pubblicazione: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
di: Donal P. McLornan, et al.
Pubblicazione: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
di: Stephen T. Oh, et al.
Pubblicazione: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
di: Ruben A. Mesa, et al.
Pubblicazione: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
di: Ruben A. Mesa, et al.
Pubblicazione: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
di: Harrison, C, et al.
Pubblicazione: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
di: McIlroy, G, et al.
Pubblicazione: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
di: Harrison, C, et al.
Pubblicazione: (2016)

The soldier and the post-conflict state
di: McMullin, J, et al.
Pubblicazione: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
di: Cross, NCP, et al.
Pubblicazione: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
di: Harrison, C, et al.
Pubblicazione: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
di: McPherson, S, et al.
Pubblicazione: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
di: Adam J. Mead, et al.
Pubblicazione: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
di: Niall P. Kelly, et al.
Pubblicazione: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
di: Psaila, B, et al.
Pubblicazione: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
di: Sousos, N, et al.
Pubblicazione: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
di: Graham McIlroy, et al.
Pubblicazione: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
di: A. Vannucchi, et al.
Pubblicazione: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
di: Chowdhury, O, et al.
Pubblicazione: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
di: Sousos, N, et al.
Pubblicazione: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
di: Greenfield, G, et al.
Pubblicazione: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
di: F. Passamonti, et al.
Pubblicazione: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
di: Butt, N, et al.
Pubblicazione: (2019)